Study Links GLP-1 Drugs to Increased Hair Loss Risk

Researchers at the University of Pennsylvania have identified a link between the use of GLP-1 drugs, such as Ozempic, and an increased risk of hair loss among patients being treated for Type 2 diabetes. The findings were published this week in The BMJ, shedding light on potential side effects of this class of medication.

The study analyzed data from 12,000 patients with Type 2 diabetes who were prescribed GLP-1 medications between 2019 and 2024, comparing them to a similar group using other treatment options. The results indicate that patients taking GLP-1 drugs experienced a greater likelihood of developing hair loss.

Specifically, users of GLP-1 drugs were 37% more likely to develop alopecia compared to patients treated with SGLT-2 inhibitors. When compared to patients on DPP-4 inhibitors, another common drug class, the incidence of hair loss was 68% higher among GLP-1 users.

Despite these figures, researchers emphasize that the absolute risk of experiencing hair loss remains very low. Only about 1.6% of the 12,000 GLP-1 users, approximately 200 individuals, developed alopecia during the study period. The study also demonstrates a correlation, not a direct causal link.

The study authors noted that while hair loss typically does not cause physical harm, it can have significant psychosocial consequences, affecting self-esteem and quality of life. They recommend increased awareness of this potential side effect to support informed treatment decisions and called for further research to clarify underlying mechanisms.